Skip to main
MRUS
MRUS logo

Merus (MRUS) Stock Forecast & Price Target

Merus (MRUS) Analyst Ratings

Based on 19 analyst ratings
Strong Buy
Strong Buy 63%
Buy 32%
Hold 5%
Sell 0%
Strong Sell 0%

Bulls say

Merus NV is positioned favorably in the clinical-stage immuno-oncology sector, particularly with its promising pipeline of bispecific antibody therapeutics, including MCLA-128, MCLA-117, and MCLA-158. The company has successfully secured FDA breakthrough therapy designation for both its first-line and second-line head and neck squamous cell carcinoma (HNSCC) indications, which significantly mitigates regulatory risks associated with ongoing Phase 3 trials. Additionally, the strong efficacy signals observed in their development programs, specifically the projected overall response rate (ORR) improvements, indicate a robust potential for competitive positioning within the market.

Bears say

Merus NV faces significant challenges in terms of visibility and predictability regarding the success of its clinical programs, particularly with lower expectations for overall survival (OS) data from the LiGeR-HN1 study. The robustness of the Phase 1/2 dataset for the “ficera” therapeutic appears questionable, complicating the regulatory path with pending decisions and no breakthrough designation (BTD) granted, which may hinder its competitive positioning. Additionally, ongoing risks related to research and development, regulatory hurdles, and potential market competition threaten Merus’s ability to achieve forecasted product sales and necessitate considerations for potentially dilutive financing beyond existing expectations.

Merus (MRUS) has been analyzed by 19 analysts, with a consensus rating of Strong Buy. 63% of analysts recommend a Strong Buy, 32% recommend Buy, 5% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Merus and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Merus (MRUS) Forecast

Analysts have given Merus (MRUS) a Strong Buy based on their latest research and market trends.

According to 19 analysts, Merus (MRUS) has a Strong Buy consensus rating as of Aug 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $70.26, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $70.26, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Merus (MRUS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.